Compare AR & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AR | CYTK |
|---|---|---|
| Founded | 2002 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 10.7B |
| IPO Year | 2013 | 2004 |
| Metric | AR | CYTK |
|---|---|---|
| Price | $40.05 | $62.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 22 |
| Target Price | $50.59 | ★ $107.39 |
| AVG Volume (30 Days) | ★ 4.3M | 1.6M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1027.78 | N/A |
| EPS | ★ 3.81 | N/A |
| Revenue | ★ $5,275,823,000.00 | $13,368,000.00 |
| Revenue This Year | $30.53 | $79.67 |
| Revenue Next Year | $2.08 | $172.23 |
| P/E Ratio | $10.70 | ★ N/A |
| Revenue Growth | ★ 21.97 | N/A |
| 52 Week Low | $31.15 | $58.05 |
| 52 Week High | $45.75 | $88.31 |
| Indicator | AR | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 59.58 | 45.85 |
| Support Level | $32.90 | $59.21 |
| Resistance Level | $45.75 | $67.65 |
| Average True Range (ATR) | 1.42 | 1.77 |
| MACD | 0.18 | 0.41 |
| Stochastic Oscillator | 66.74 | 48.20 |
Antero Resources is an exploration and production firm whose operations represent a pure play in the Marcellus Shale, located in northern West Virginia. The company started in 2002 as an E&P focused on the Barnett Shale (Fort Worth, Texas). Antero redefined itself in Appalachia's Marcellus Shale in 2005. In 2012, shortly before Antero's 2013 IPO, Antero Midstream Partners was formed to handle the company's rapidly growing gas volumes. In 2026, the firm narrowed its focus further by selling its Ohio Utica assets and using the proceeds to acquire additional Marcellus acreage from HG Energy. Just over half of its production and earning power is tied to natural gas, with the remainder mostly NGLs, where it holds a leading position, and some crude oil.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.